According to a recent article in the New York Times, the anti-clotting drug Pradaxa has been linked with more than 500 deaths in the United States. Pradaxa is used to prevent strokes in people with atrial fibrillation, a heart-rhythm disorder.
On the market only two years, Pradaxa is growing in popularity for its ease of use, but it has been associated with hemorrhaging, and it has no antidote to reverse its blood-thinning effects. According the FDA, approximately 725,000 patients in the United States, including Connecticut, have used Pradaxa.
Pradaxa, which is also known as dabigatran, is made by German drug company Bohringer Ingelheim, whose US subsidiary, Bohringer Ingelheim Pharmaceuticals, is headquartered in Ridgefield, CT. Since the drug’s introduction, it has brought in more than $1 billion in sales for Bohringer Ingelheim.